Autopsy report · NCT01170650

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

“DSMB decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 4 years 5 months before it stopped.
• 441 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Endocyte

Sponsor type

Industry

Conditions

Ovarian Cancer

Interventions

EC145; Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); placebo; EC20

Participants

441

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.